First-line immunotherapy is a standard treatment for patients with advanced non-small cell lung cancer. Prof. Gerard Zalcman (Bichat Hospital, Assistance Publique-Hôpitaux de Paris; Institute of Cancer AP-HP Nord, Paris, France) joins touchONCOLOGY to discuss the IFCT-1701 phase III trial, investigating nivolumab plus ipilimumab, aiming to assess if 6-months nivolumab/ipilimumab duration was equivalent to continuation until progression in patients with disease control.
The abstract entitled ‘Nivolumab (Nivo) plus ipilimumab (Ipi) 6-months treatment versus continuation in patients with advanced non-small cell lung cancer (aNSCLC): Results of the randomized IFCT-1701 phase III trial‘ Abstract 972O, was presented at European Society for Medical Oncology (ESMO) 2022.
Questions:
- What is the basis of the standard 2 years duration of immunotherapy with advanced NSCLC and no targetable mutation? (0:21)
- What were the aims, design and eligibility criteria of your study? (0:50)
- What were the findings of the study in terms of disease progression? (2:04)
- What were the reasons for the premature halt of the trial? (2:44)
- What further investigation is planned? (3:02)
Disclosures: Gerard Zalcman receives grant/research support from Fondation ROCHE (France); is on the advisory board for BMS, Pfizer, Astra-Zeneca, Takeda, Inventiva, and PAredox therapeuticals; and receives honoraria/honorarium from BMS, Astra-Zeneca, and Pfizer.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Katey Gabrysch.
